These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39080217)

  • 1. Establishment and characterization of a novel MDM2/MYCN-co-amplified neuroblastoma cell line, NBN-SHIM, established from a late recurrent stage MS tumor.
    Kato K; Nagai JI; Goto H; Shinkai M; Kitagawa N; Toyoda Y; Nishi T; Kigasawa H; Tanaka M; Kurosawa K; Ito Y; Haruta M; Kamijo T; Yoshimi A; Tsuchida M; Nagahara N; Tanaka Y
    Hum Cell; 2024 Sep; 37(5):1602-1609. PubMed ID: 39080217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
    Amoroso L; Ognibene M; Morini M; Conte M; Di Cataldo A; Tondo A; D'Angelo P; Castellano A; Garaventa A; Lasorsa VA; Podestà M; Capasso M; Pezzolo A
    Genes Chromosomes Cancer; 2020 May; 59(5):277-285. PubMed ID: 31756773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup.
    Martinez-Monleon A; Kryh Öberg H; Gaarder J; Berbegall AP; Javanmardi N; Djos A; Ussowicz M; Taschner-Mandl S; Ambros IM; Øra I; Sandstedt B; Beiske K; Ladenstein R; Noguera R; Ambros PF; Gordon Murkes L; Ljungman G; Kogner P; Fransson S; Martinsson T
    Sci Rep; 2022 Jul; 12(1):12420. PubMed ID: 35859155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
    Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
    Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
    He J; Gu L; Zhang H; Zhou M
    Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line.
    Corvi R; Savelyeva L; Amler L; Handgretinger R; Schwab M
    Eur J Cancer; 1995; 31A(4):520-3. PubMed ID: 7576957
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    De Rosa P; Severi F; Zadran SK; Russo M; Aloisi S; Rigamonti A; Capranico G; Milazzo G; Perini G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
    Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
    Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
    Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma.
    Corvi R; Savelyeva L; Breit S; Wenzel A; Handgretinger R; Barak J; Oren M; Amler L; Schwab M
    Oncogene; 1995 Mar; 10(6):1081-6. PubMed ID: 7700632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells.
    Gu L; Zhang H; He J; Li J; Huang M; Zhou M
    Oncogene; 2012 Mar; 31(11):1342-53. PubMed ID: 21822304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A
    Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
    Slack A; Lozano G; Shohet JM
    Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
    Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
    Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
    Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
    Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.